Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients

Journal of Cellular Biochemistry

Volumn 113, Issue 6, 2012, Pages 2122-2125

  Gangemi, Sebastiano ^a,b   Minciullo, Paola ^a   Adamo, Barbara ^a   Franchina, Tindara ^a   Ricciardi, Giuseppina R R ^a   Ferraro, Maria ^b   Briguglio, Roberta ^a   Toscano, Giuseppe ^a   Saitta, Salvatore ^a   Adamo, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

BREAST CANCER; INTERLEUKIN 23; Th17 CELLS

Indexed keywords

CYTOKINE; INTERLEUKIN 23;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SERUM; STATISTICAL SIGNIFICANCE; TH17 CELL; TREATMENT OUTCOME; TUMOR IMMUNOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-23; MIDDLE AGED; PROGNOSIS;

EID: 84859613828     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24083     Document Type: Article

References (17)

1. Adamo V, Franchina T, Minciullo PL, Pace E, Colonese F, Ricciardi GR, Saitta S, Ferraro M, Spatari G, Gangemi S,. 2011. Role of Interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: Preliminary data and future perspectives. J Cell Physiol 226: 3032-3034.
2. De Nardo DG, Coussens LM,. 2007. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9 (4): 212.
3. Goldberg JE, Schwertfeger KL,. 2010. Proinflammatory cytokines in breast cancer: Mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11 (9): 1133-1146.
4. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J,. 2009. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 100 (7): 1061-1067.
5. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H,. 2007. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 178 (12): 7571-7580.
6. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W,. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178 (11): 6730-6733.
7. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M,. 2006. IL-23 promotes tumour incidence and growth. Nature 442 (7101): 461-465.
8. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F,. 2008. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 226: 112-131.
9. Nicolini A, Carpi A, Rossi G,. 2006. Cytokines in breast cancer. Cytokine Growth Factor Rev 17 (5): 325-337.
10. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA,. 2000. Novel p19 protein engages IL-12p40 to form a cytokin, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (5): 715-725.
11. Prat A, Perou CM,. 2011. Deconstructing the molecular portraits of breast cancer. Mol Oncol 5 (1): 5-23.
12. Spolski R, Leonard WJ,. 2009. Cytokine mediators of Th17 function. Eur J Immunol 39 (3): 658-661.
13. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G,. 2010. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184 (3): 1630-1641.
14. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, Essler M,. 2006. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177 (11): 8266-8272.
15. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T,. 2010. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010.
16. Zamarron BF, Chen W,. 2011. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7 (5): 651-658.
17. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G,. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374 (3): 533-537.